|
|
||||||||
Department of Medicine, Rosalind Russell Research Laboratory, San Francisco General Hospital, and University of California, San Francisco, CA 94143
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The mechanisms of signal transduction by CD28 are not completely
understood. CD28 has a cytoplasmic domain of
40 amino acids that is
highly conserved across species and that contains four tyrosine
residues 2 . Several lines of evidence suggest that phosphorylation of
one or more of these cytoplasmic tyrosine is important for the delivery
of the CD28 costimulus. First, crosslinking of CD28 by mAbs induces its
tyrosine phosphorylation in Jurkat cells and T cell hybridoma cells 8, 9 . Second, mutation of all four cytoplasmic tyrosine residues of mouse
CD28 (mCD28)4 significantly
impairs its ability to costimulate the production of IL-2 10, 11 .
Finally, although phosphorylation of Tyr170 (murine
sequence) has not been demonstrated directly, there is circumstantial
evidence that its phosphorylation recruits phosphatidylinositol
3-kinase (PI3K) to CD28 8, 12, 13, 14, 15, 16, 17 . There are conflicting data as to
whether the costimulation of IL-2 production by CD28 requires
Tyr170 and the recruitment of PI3K 10, 11, 16, 17, 18, 19, 20, 21 .
In this study, we used a series of mutants of mCD28 expressed in Jurkat cells to determine phosphorylation sites. As expected, we found that stimulation of mCD28 induced the phosphorylation of Tyr170. We also identified a second site of phosphorylation, Tyr188. We observed phosphorylation of Tyr188 after mAb crosslinking or engagement by the natural ligand, B7.2. Mutation of Tyr188 to Phe severely impaired the ability of mCD28 to deliver a costimulus in Jurkat cells, suggesting that phosphorylation of Tyr188 plays a critical role in signaling through CD28.
| Materials and Methods |
|---|
|
|
|---|
Murine mAb 9.3 (IgG2a) to human CD28 (hCD28) and hamster mAb
37.51 specific for mCD28 were kind gifts of Drs. Jeffrey Ledbetter
(Bristol-Meyers Squibb Pharmaceutical Research Institute, Seattle, WA)
and James Allison (University of California, Berkeley, CA),
respectively. Mouse mAb G46-2.6 (IgG1) to human class I-MHC Ags and
mouse mAb 34-2-12 (IgG2a) against mouse class I-MHC Ag
H-2Dd were obtained from PharMingen (San Diego, CA) and
were dialyzed overnight against PBS to remove their sodiumazide
preservative. The horseradish peroxidase- (HRP-) conjugated
antiphosphotyrosine mAb 4G10-HRP was purchased from Upstate
Biotechnology (Lake Placid, NY). Because CD28 is also phosphorylated on
serine and threonine 22 , we confirmed the specificity of 4G10-HRP by
immunoblotting in the presence of saturating levels of
phosphothreonine, phosphoserine, and phosphotyrosine solutions. Only
phosphotyrosine blocked the 4G10-HRP (data not shown). Rabbit antisera
to the p85
subunit of PI3K (p85
Z-8), goat antisera to hCD28
(CD28 N-20) and mCD28 (CD28 M-20), and HRP-conjugated anti-goat Ig
and anti-mouse Ig reagents were from Santa Cruz Biotechnology
(Santa Cruz, CA).
Cells
Jurkat E6-1 cells and Rat2 embryonic fibroblast cells (American
Type Culture Collection, Manassas, VA) were maintained in
"complete" RPMI medium composed of RPMI 1640 supplemented with 100
U/ml penicillin, 100 µg/ml streptomycin, and 10% heat-inactivated
FCS (Life Technologies, Gaithersburg, MD). Jurkat clones expressing
wild-type (WT) mCD28, and the ALL F, F170, Y170, Y185, Y188, and Y197
mutants have been described 10, 21 . The F185, F188, and F197 mCD28
mutants were made by PCR-mediated site-directed mutagenesis, subcloned
into the expression vector pBSR
EN (a gift of Drs. Andrey S. Shaw and
Michael W. Olszowy, Washington University School of Medicine, St.
Louis, MO), and used to stably transfect Jurkat cells as described
21 . Clones that expressed mCD28 at levels comparable to the WT
mCD28-expressing Jurkat cells were selected for study. The transfected
Jurkat cells were passaged in complete RPMI medium supplemented with 2
mg/ml G418 (Life Technologies). Rat2 cells that expressed mouse B7.2
were produced by electroporation of Rat2 rat fibroblast cells with a
pcDNA1.1 (Invitrogen, Carlsbad, CA) vector containing the mouse B7.2
cDNA (from Dr. Peter Linsley, Bristol-Meyers Squibb Pharmaceutical
Research Institute) followed by selection in complete RPMI medium
supplemented with 1 mg/ml G418 and analysis by flow cytometry. For
studies of mouse splenocytes, a single cell suspension, prepared from
the spleens of 12-wk-old female BALB/c mice, was cultured in complete
RPMI medium with 5 µg/ml Con A (Sigma, St. Louis, MO) and 50 U/ml
mouse IL-2 (Genzyme Diagnostics, Cambridge, MA) for 72 h before
use.
Cell activation, immunoprecipitation, and immunoblotting
For mAb crosslinking experiments, Jurkat cells were washed twice with ice-cold complete RPMI medium and resuspended at 1 x 108 cells/ml. The samples were warmed to room temperature for 5 min, then to 37°C for 5 min. The primary mAb was added at 10 µg/ml. In crosslinking experiments, the secondary crosslinking Ab was added at 40 µg/ml after 2 min. For stimulation of Jurkat cells by Rat2 cells, 1.5 x 108 Jurkat cells were pelleted with 2.5 x 107 Rat2 cells by a 10-s cenrifugation at 1700 x g in a microfuge and then incubated at 37°C. At the end of the incubation periods, mAb-stimulated Jurkat cells and the Jurkat cell/Rat2 cell mixture were pelleted in a microfuge, lysed with Nonidet P-40 lysis buffer (150 mM NaCl, 10 mM Tris-HCl (pH 7.5), 1% Nonidet P-40; 0.5 mM EDTA, 20 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 1 µg/ml leupeptin, 10 µg/ml aprotinin, 0.5 µg/ml pepstatin, and 2 µg/ml antipain), and left on ice for 15 min. For samples receiving no primary mAb stimulation, appropriate mAbs were added at this point. The lysates were centrifuged at 21,000 x g at 4°C to remove insoluble material, and 20 µl of packed Ultralink protein A/G beads (Pierce, Rockford, IL) were added to the resulting supernatants. After incubation for 1 h on a rotor at 4°C, the bead-captured immune complexes were washed five times with the Nonidet P-40 lysis buffer. The immune complexes were solubilized in either reducing (containing freshly added 1% 2-ME) or nonreducing (containing freshly made 5 mM sodium iodoacetamide) Laemmli sample buffer. The samples were heated to 95°C for 10 min and then run on 10% SDS polyacrylamide gels. The separated proteins were transferred to polyvinylidene fluoride membranes using a Hoefer Scientific Instruments (San Francisco, CA) semidry transfer apparatus. After an initial air drying and rewetting in methanol and water, the membranes were blocked for 30 min at 42°C in BSA PBS blocking buffer (PBS, 0.1% Tween 20, and 5% BSA; Sigma). After immunoblot analysis with antiphosphotyrosine, the membranes were stripped with 2% SDS at 42°C for 30 min. The membranes were reblocked with PBS blocking buffer containing PBS, 0.1% Tween 20, and 10% nonfat milk, and reprobed with anti-p85 PI3K antiserum. After a second stripping and blocking, the membranes were probed with anti-CD28 antiserum. Immunoblot signals were detected with enhanced chemiluminescence using Renaissance Western Plus Reagent from NEN Life Sciences (Boston, MA). Each lane corresponds to immunoprecipitates from 1.5 x 108 cells.
IL-2 assay and measurements
IL-2 levels were measured in supernatants obtained from 50,000 Jurkat cells incubated in 200 µl of complete RPMI medium for 16 h at 37°C in room air supplemented with 5% CO2. Cells were stimulated with 1 ng/ml PMA plus 0.5 µM ionomycin and, as indicated, 5 µg/ml of either anti-human MHC class I, anti-hCD28, or anti-mCD28. IL-2 was quantified using a human IL-2 ELISA kit from Immunotech (Westbrook, ME). Optical density readings of the samples were performed on a SpectraMax 250 reader from Molecular Devices (Sunnyvale, CA).
Costimulation of CD69 expression
For measurement of CD69 induction, 105 Jurkat cells were stimulated with 5 ng/ml PMA or with 5 ng/ml PMA plus 5 µg/ml of either anti-hCD28, anti-mCD28, or control hamster IgG anti-trinitrophenol (TNP) for 2 h at 37°C in room air supplemented with 5% CO2. The cells were then washed with ice-cold staining wash buffer (PBS with 0.1% sodium azide and 3% FCS). The washed cells were stained with 1 µg of anti-hCD69 FITC-conjugated Ab. An isotype-matched, nonreactive FITC-conjugated Ab (anti-hCD19) was used as a negative control. The stained cells were then extensively washed with ice-cold staining wash buffer, and their surface staining was analyzed and profiled by a FACSort program and a Becton Dickinson FACScan instrument (Becton Dickinson, Sparks, MD).
| Results |
|---|
|
|
|---|
As reported previously, stimulation of CD28 by mAbs induced its
tyrosine phosphorylation in human Jurkat cells and hCD28-transfected
murine T hybridoma cells (Fig. 1
) 8, 9 .
Similarly, we find that mAb-mediated crosslinking triggered the
tyrosine phosphorylation of mCD28 in mouse splenic T cells and of mCD28
when it is expressed in Jurkat cells after gene transfer (Figs. 1
and 2
). To establish that the anti-CD28
immunoprecipitated phosphotyrosine band was indeed CD28, the samples
were electrophoresed under both reducing and nonreducing conditions.
Consistent with the expression of CD28 as a covalently linked homodimer
2 , the band corresponding to CD28 migrated at a molecular mass
of 7590 kDa under nonreducing conditions and 3545 kDa under
reducing conditions (Fig. 1
B). As shown, the tyrosine
phosphorylated candidate band comigrated with CD28 under both reducing
and nonreducing conditions confirming its identity as CD28.
|
|
5 min, and persisted for at least 30 min (Fig. 2Tyr170 and Tyr188 of mCD28 are sites of phosphorylation
The ability of Jurkat cells to support the tyrosine
phosphorylation of mCD28 allowed us to examine a series of mCD28
mutants with phenylalanine to tyrosine mutations (shown schematically
in Fig. 3
) to determine specific sites of
tyrosine phosphorylation. We selected stable Jurkat transfectants
expressing comparable cell surface levels of WT mCD28 and the mCD28
mutants for analysis and used a mAb specific for mCD28 to selectively
crosslink the transfected mCD28. In parallel experiments, the
endogenous hCD28 was stimulated by a mAb specific for hCD28 (Fig. 4
A).
|
|
We then examined mutants that preserved a single cytoplasmic tyrosine
residue with the remaining three mutated to phenylalanine. Of these,
the Y170 and Y188 mutants exhibited a low level of basal tyrosine
phosphorylation that increased substantially after mAb-mediated
stimulation (Fig. 4
A). In contrast, we did not detect
phosphorylation of the Y185 and Y197 mutants in either unstimulated or
stimulated cells, even though mAb crosslinking induced tyrosine
phosphorylation of hCD28 in the Y185- and Y197-expressing cells.
Therefore, Tyr170 and Tyr188 are sites of mCD28
phosphorylation in Jurkat cells whereas Tyr185 and
Tyr197 are either not phosphorylated under these conditions
or are phosphorylated at levels below the limits of detection.
Consistent with the conclusion that both Tyr170 and
Tyr188 are phosphorylated, single mutation to phenylalanine
at either position 170 or 188 did not prevent tyrosine phosphorylation
of mCD28 (F170 and F188 mutants; Fig. 4
B). However, mutation
of Tyr188 had a more impressive inhibitory effect on mCD28
phosphorylation than did mutation of Tyr170 (Fig. 4
B). As previously reported by ourselves and others,
Tyr170 is required for the recruitment of PI3K to mCD28
13, 14, 15, 16, 17, 18, 19, 20, 21, 22 . Among the mCD28 mutants expressing single tyrosine residues,
only Y170 recruited PI3K p85, and a single mutation to phenylalanine at
position 170 (the F170 mutant) abrogated the association with PI3K
(Fig. 4
B), as reported 21 .
Interaction with B7.2, the natural ligand of CD28, induces tyrosine phosphorylation of WT mCD28 and the Y188 mutant form of mCD28
To determine whether CD28 is tyrosine phosphorylated after
interactions with its natural ligands, we incubated WT mCD28-expressing
Jurkat cells with either Rat2 cells or Rat2 cells that express high
levels of mouse B7.2 (B7 Rat2) after gene transfer. Interaction with
the B7.2-expressing cells induced readily detectable tyrosine
phosphorylation of mCD28 within 2 min, and the phosphorylation
persisted for at least 10 min (Fig. 5
A). Recruitment of the
p85 subunit of PI3K to mCD28 after similar kinetics, indicating that
engagement by B7.2 triggers the phosphorylation of Tyr170.
To determine whether phosphorylation of Tyr188 is also
induced by binding B7.2, we incubated Y188-expressing Jurkat cells with
the B7 Rat2 cells. As was the case with mAb-mediated crosslinking,
incubation with B7 Rat2 cells led to the tyrosine phosphorylation of
the Y188 mutant (Fig. 5
). The kinetics of tyrosine phosphorylation for
Y188 were somewhat slower than for WT mCD28 and there was no
recruitment of p85 subunit of PI3K to the phosphorylated Y188 mutant.
|
Perturbation of CD28 delivers a costimulus that enhances a number of T cell responses. In Jurkat, CD28 stimulation promotes CD69 expression by PMA-treated cells and augments IL-2 production induced by the combination of ionomycin and PMA. We used these responses to assess the functional consequences of mutations of the tyrosine phosphorylation sites. Because subclones of Jurkat differ in the magnitude of their responses to activation 10, 21 , we compared the costimulatory ability of the mCD28 mutants to that of the endogenous hCD28 expressed by each subclone.
PMA induces Jurkat cells to express CD69, an early activation Ag, and
stimulation of CD28 enhances this response. WT mCD28, as well as the
F185 and the F197 mutants, delivered costimuli for CD69 expression that
were only slightly less effective than costimulation by the endogenous
hCD28 expressed by each Jurkat subclone (Fig. 6
A). Mutation of the
Tyr170 phosphorylation site to phenylalanine did not impair
the ability of mCD28 to promote the expression of CD69 in PMA-treated
Jurkat cells; indeed, the F170 mutant was more effective than the
endogenous hCD28 in delivering this costimulus. Quite different results
were obtained with mutation of the Tyr188 phosphorylation
site. Mutation of Tyr188 to phenylalanine severely
diminished the ability of mCD28 to promote the expression of CD69 (F188
mutant; Fig. 6
A). The functional impairment exhibited by the
F188 mutant was similar to that of the ALL F mutant, which lacks
cytoplasmic tyrosine residues. When tyrosine was retained at position
Y188 and the remaining three tyrosine residues were mutated to
phenylalanine (Y188 mutant), mCD28 retained its ability to costimulate
expression of CD69 (Fig. 6
B). Thus, in terms of CD28
cytoplasmic tyrosine residues, Tyr188 is both necessary and
sufficient for the delivery of a costimulus in this particular system.
|
|
| Discussion |
|---|
|
|
|---|
In Jurkat cells, the functional consequences of the mutation of
Tyr188 are unique among mCD28 tyrosine residues; mutation
at any of the other three tyrosine residues does not diminish
costimulation of CD69 expression or IL-2 production. Moreover,
preservation of Tyr188 permits mCD28 to deliver costimuli
even when the other three tyrosine residues have been mutated to
phenylalanine (Figs. 6
and 7
) 10 . Therefore, in terms of CD28
cytoplasmic tyrosine residues, Tyr188 is both necessary and
sufficient for costimulation in the Jurkat system.
The functional consequences of the mutation of Tyr188 to
Phe raise the possibility that phosphorylation of Tyr188
recruits to CD28 a signaling molecule involved in costimulation. The
nature of the Tyr188-based signal is currently unknown.
CD28 signaling events include the recruitment and activation of PI3K
8, 12, 13, 14, 15, 17 and the delivery of a signal that promotes TCR-mediated
activation of Jun N-terminal kinase 25, 26 . However, neither pathway
requires the integrity of Tyr188, and neither appears to be
involved in the Tyr188-based signal (Fig. 4
and our
unpublished observations). Mutation of Tyr188 to Phe does
not abrogate the recruitment of PI3K to mCD28 (F188 mutant; Fig. 4
B). We have found that truncation of the mCD28 at position
182 does not alter its ability to synergize with the TCR in the
activation of Jun N-terminal kinase, even though this deletes
Tyr188 (our unpublished observations).
As noted, the identification of Tyr170 as a phosphorylation site was anticipated. Tyr170 lies within a sequence motif that, when phosphorylated, is predicted to form a high affinity binding site for the SH2 domains of PI3K p85 subunit 8, 12, 13, 14, 15, 17 and also has been reported to bind the Grb2 adapter protein 27 . The association of CD28 with PI3K p85 depends upon Tyr170, and observations with synthetic peptides corresponding to this region indicate that Tyr170 must be phosphorylated to bind PI3K p85 13, 14, 15 . These findings together with the direct evidence presented here establish that ligand-induced phosphorylation of Tyr170 recruits PI3K to CD28.
The functional significance of the recruitment of PI3K to
Tyr170 depends upon the cell system studied. In several
systems, Tyr170 (or its human equivalent) is required for
costimulation and mutation of this site to phenylalanine abrogates CD28
costimulation 8, 28 . However, in Jurkat cells, mutation of
Tyr170 to phenylalanine prevents the recruitment of PI3K to
mCD28 but does not impair the ability of mCD28 to promote IL-2
production 21, 29 or to enhance CD69 expression (Fig. 6
). Activation
of PI3K inhibits the transcriptional capacity of NF of activated T
cells (NF-AT) in Jurkat cells, indicating that PI3K can function as a
negative regulator of TCR signaling events 30 . Wortmannin, an
inhibitor of PI3K, prevents Ag-induced IL-2 production by freshly
isolated T cells from DO11.10 TCR transgenic mice 31 . However, the
wortmannin-sensitive step does not appear to be at the level of CD28
costimulation of IL-2 production. Wortmannin inhibits conjugate
formation between T cells and APCs, an event that does not depend upon
CD28 31 . When the TCR and CD28 are engaged by mAbs, wortmannin
enhances IL-2 production by DO11.10 T cells, an observation consistent
with the negative regulatory role for PI3K defined in Jurkat cells
31 .
Interestingly, the two phosphorylation sites identified here, Tyr170 and Tyr188, are the only cytoplasmic tyrosine residues conserved between CD28 and CTLA-4 2, 32, 33 , a related molecule that functions primarily to shut Tyr188, are the only cytoplasmic tyrosine residues conserved between CD28 and T cell activation 34 . The homologue of Tyr170 is a regulator of the cell surface expression of CTLA-4 and may recruit PI3K and the tyrosine phosphatase SYP to CTLA-4 35, 36, 37 . The functional significance of the homologue of Tyr188 is not known.
In contrast to the results obtained with Tyr170 and
Tyr188, we did not detect tyrosine phosphorylation of
Tyr185 or Tyr197 of mCD28 (Fig. 4
).
Tyr185 and Tyr197 could be phosphorylated at
levels below the limitations of detection or under activation
conditions other than those studied here. It is also possible that
their phosphorylation requires the integrity of another CD28
cytoplasmic tyrosine residue. In that case, our strategy of using
mutants that express single tyrosine residues would prevent us from
observing phosphorylation on these sites. Tyr185 and
Tyr197 are not necessary for mCD28 to promote CD69
expression in PMA-treated Jurkat cells or to augment IL-2 production in
response to ionomycin plus PMA (Fig. 6
and 7
). Therefore, these
tyrosine residues do not generate critical costimulatory signals in
this system, but we cannot rule out the possibility that our
experimental conditions rendered signals based on Tyr185
and Tyr197 unnecessary.
In summary, we have identified two sites of tyrosine phosphorylation of CD28: Tyr170, whose phosphorylation recruits and activates PI3K; and Tyr188, whose integrity, we find, is required for costimulation. These studies support the hypothesis that CD28 signaling involves its tyrosine phosphorylation and pinpoint the phosphorylation of Tyr188 as a critical step in the delivery of a costimulus.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Current address: Merck Research Laboratories, 126 East Lincoln Avenue, P.O. Box 2000, RY32-645, Rahway NJ 07065. ![]()
3 Address correspondence and reprint requests to Dr. John Imboden, Box 0868, University of California, San Francisco, CA 94143. E-mail address: ![]()
4 Abbreviations used in this paper: m, mouse; h, human; PI3K, phosphatidylinositol 3-kinase; WT, wild type. ![]()
Received for publication July 22, 1998. Accepted for publication November 2, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Sanchez-Lockhart, B. Graf, and J. Miller Signals and Sequences That Control CD28 Localization to the Central Region of the Immunological Synapse J. Immunol., December 1, 2008; 181(11): 7639 - 7648. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Hofinger, H. Sticht, R. Tavano, and A. Viola Multiple Modes of Interaction between Lck and CD28 J. Immunol., April 1, 2005; 174(7): 3839 - 3840. [Full Text] [PDF] |
||||
![]() |
A. Sadra, T. Cinek, and J. B. Imboden Translocation of CD28 to lipid rafts and costimulation of IL-2 PNAS, August 3, 2004; 101(31): 11422 - 11427. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Cook, L. Albacker, A. August, and A. J. Henderson CD28-dependent HIV-1 Transcription Is Associated with Vav, Rac, and NF-{kappa}B Activation J. Biol. Chem., September 12, 2003; 278(37): 35812 - 35818. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Cook, A. August, and A. J. Henderson Recruitment of Phosphatidylinositol 3-Kinase to CD28 Inhibits HIV Transcription by a Tat-Dependent Mechanism J. Immunol., July 1, 2002; 169(1): 254 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Arrington, D. N. McMurray, K. C. Switzer, Y.-Y. Fan, and R. S. Chapkin Docosahexaenoic Acid Suppresses Function of the CD28 Costimulatory Membrane Receptor in Primary Murine and Jurkat T Cells J. Nutr., April 1, 2001; 131(4): 1147 - 1153. [Abstract] [Full Text] |
||||
![]() |
T. Cinek, A. Sadra, and J. B. Imboden Cutting Edge: Tyrosine-Independent Transmission of Inhibitory Signals by CTLA-4 J. Immunol., January 1, 2000; 164(1): 5 - 8. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Holdorf, J. M. Green, S. D. Levin, M. F. Denny, D. B. Straus, V. Link, P. S. Changelian, P. M. Allen, and A. S. Shaw Proline Residues in Cd28 and the Src Homology (Sh)3 Domain of Lck Are Required for T Cell Costimulation J. Exp. Med., August 2, 1999; 190(3): 375 - 384. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |